Cargando…

Clinical predictive risk factors prolonged the duration of SARS-CoV-2 clearance in 279 moderate COVID-19 patients: A multicenter retrospective cohort study

The results of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid as one of the criteria has been widely applied to assess whether the coronavirus disease 2019 (COVID-19) patients could discharge, however, the risk factors that affect the duration of the SARS-CoV-2 clearance r...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xinxin, Zhou, Shuang, Liu, Changya, Huang, Tingrong, Zheng, You, Zhang, Wen, Qu, Yao, Fang, Bangjiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500613/
https://www.ncbi.nlm.nih.gov/pubmed/34622847
http://dx.doi.org/10.1097/MD.0000000000027410
_version_ 1784580483669032960
author Wu, Xinxin
Zhou, Shuang
Liu, Changya
Huang, Tingrong
Zheng, You
Zhang, Wen
Qu, Yao
Fang, Bangjiang
author_facet Wu, Xinxin
Zhou, Shuang
Liu, Changya
Huang, Tingrong
Zheng, You
Zhang, Wen
Qu, Yao
Fang, Bangjiang
author_sort Wu, Xinxin
collection PubMed
description The results of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid as one of the criteria has been widely applied to assess whether the coronavirus disease 2019 (COVID-19) patients could discharge, however, the risk factors that affect the duration of the SARS-CoV-2 clearance remained to be an enigma. Our research was to identify risk factors correlated with prolonged duration of the SARS-CoV-2 clearance in moderate COVID-19 patients. We retrospectively analyzed 279 consecutive ordinary COVID-19 patients in 3 hospitals in Hubei province including Huangshi Hospital of Infectious Disease, Wuhan Thunder God Mountain Hospital, and Tongji Hospital. Eight clinical characters were contained as risk factors. We used a logistic regression model and nomogram to assess the possibility that the SARS-CoV-2 nucleic acid may turn negative in 14 days. Time from symptoms onset to diagnosis (odds ratio [OR] = 3.18; 95% confidence interval [CI] 1.56–6.46; P = .001), time from onset use of antiviral drugs to onset of symptoms (OR = 0.41; 95% CI 0.23–0.72; P = .02), and bacterial coinfection (OR = 0.07; 95% CI 0.01–0.86; P = .038) were independent risks factors for the duration of SARS-CoV-2 nucleic acid clearance. The regression model showed good accuracy and sensitivity (area under the curve  = 0.96). Nomogram was also provided to predict the negative conversion rate of SARS-CoV-2 nucleic acids within 14 days. Time from symptoms onset to diagnosi, time from onset use of antiviral drugs to onset of symptoms, and bacterial coinfection were independent risk factors for the time of SARS-CoV-2 nucleic acid turning negative in ordinary COVID-19 patients. However, the age, gender, underlying disease, fungal coinfection, and duration use of antiviral drugs were irrelevant factors.
format Online
Article
Text
id pubmed-8500613
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-85006132021-10-12 Clinical predictive risk factors prolonged the duration of SARS-CoV-2 clearance in 279 moderate COVID-19 patients: A multicenter retrospective cohort study Wu, Xinxin Zhou, Shuang Liu, Changya Huang, Tingrong Zheng, You Zhang, Wen Qu, Yao Fang, Bangjiang Medicine (Baltimore) 3700 The results of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid as one of the criteria has been widely applied to assess whether the coronavirus disease 2019 (COVID-19) patients could discharge, however, the risk factors that affect the duration of the SARS-CoV-2 clearance remained to be an enigma. Our research was to identify risk factors correlated with prolonged duration of the SARS-CoV-2 clearance in moderate COVID-19 patients. We retrospectively analyzed 279 consecutive ordinary COVID-19 patients in 3 hospitals in Hubei province including Huangshi Hospital of Infectious Disease, Wuhan Thunder God Mountain Hospital, and Tongji Hospital. Eight clinical characters were contained as risk factors. We used a logistic regression model and nomogram to assess the possibility that the SARS-CoV-2 nucleic acid may turn negative in 14 days. Time from symptoms onset to diagnosis (odds ratio [OR] = 3.18; 95% confidence interval [CI] 1.56–6.46; P = .001), time from onset use of antiviral drugs to onset of symptoms (OR = 0.41; 95% CI 0.23–0.72; P = .02), and bacterial coinfection (OR = 0.07; 95% CI 0.01–0.86; P = .038) were independent risks factors for the duration of SARS-CoV-2 nucleic acid clearance. The regression model showed good accuracy and sensitivity (area under the curve  = 0.96). Nomogram was also provided to predict the negative conversion rate of SARS-CoV-2 nucleic acids within 14 days. Time from symptoms onset to diagnosi, time from onset use of antiviral drugs to onset of symptoms, and bacterial coinfection were independent risk factors for the time of SARS-CoV-2 nucleic acid turning negative in ordinary COVID-19 patients. However, the age, gender, underlying disease, fungal coinfection, and duration use of antiviral drugs were irrelevant factors. Lippincott Williams & Wilkins 2021-10-08 /pmc/articles/PMC8500613/ /pubmed/34622847 http://dx.doi.org/10.1097/MD.0000000000027410 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
spellingShingle 3700
Wu, Xinxin
Zhou, Shuang
Liu, Changya
Huang, Tingrong
Zheng, You
Zhang, Wen
Qu, Yao
Fang, Bangjiang
Clinical predictive risk factors prolonged the duration of SARS-CoV-2 clearance in 279 moderate COVID-19 patients: A multicenter retrospective cohort study
title Clinical predictive risk factors prolonged the duration of SARS-CoV-2 clearance in 279 moderate COVID-19 patients: A multicenter retrospective cohort study
title_full Clinical predictive risk factors prolonged the duration of SARS-CoV-2 clearance in 279 moderate COVID-19 patients: A multicenter retrospective cohort study
title_fullStr Clinical predictive risk factors prolonged the duration of SARS-CoV-2 clearance in 279 moderate COVID-19 patients: A multicenter retrospective cohort study
title_full_unstemmed Clinical predictive risk factors prolonged the duration of SARS-CoV-2 clearance in 279 moderate COVID-19 patients: A multicenter retrospective cohort study
title_short Clinical predictive risk factors prolonged the duration of SARS-CoV-2 clearance in 279 moderate COVID-19 patients: A multicenter retrospective cohort study
title_sort clinical predictive risk factors prolonged the duration of sars-cov-2 clearance in 279 moderate covid-19 patients: a multicenter retrospective cohort study
topic 3700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500613/
https://www.ncbi.nlm.nih.gov/pubmed/34622847
http://dx.doi.org/10.1097/MD.0000000000027410
work_keys_str_mv AT wuxinxin clinicalpredictiveriskfactorsprolongedthedurationofsarscov2clearancein279moderatecovid19patientsamulticenterretrospectivecohortstudy
AT zhoushuang clinicalpredictiveriskfactorsprolongedthedurationofsarscov2clearancein279moderatecovid19patientsamulticenterretrospectivecohortstudy
AT liuchangya clinicalpredictiveriskfactorsprolongedthedurationofsarscov2clearancein279moderatecovid19patientsamulticenterretrospectivecohortstudy
AT huangtingrong clinicalpredictiveriskfactorsprolongedthedurationofsarscov2clearancein279moderatecovid19patientsamulticenterretrospectivecohortstudy
AT zhengyou clinicalpredictiveriskfactorsprolongedthedurationofsarscov2clearancein279moderatecovid19patientsamulticenterretrospectivecohortstudy
AT zhangwen clinicalpredictiveriskfactorsprolongedthedurationofsarscov2clearancein279moderatecovid19patientsamulticenterretrospectivecohortstudy
AT quyao clinicalpredictiveriskfactorsprolongedthedurationofsarscov2clearancein279moderatecovid19patientsamulticenterretrospectivecohortstudy
AT fangbangjiang clinicalpredictiveriskfactorsprolongedthedurationofsarscov2clearancein279moderatecovid19patientsamulticenterretrospectivecohortstudy